These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22299825)

  • 41. Inhaled Formulation Design for the Treatment of Lung Infections.
    Garcia-Contreras L; Yadav KS
    Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters.
    Dong L; Zhuang X
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deposition, imaging, and clearance: what remains to be done?
    Scheuch G; Bennett W; Borgström L; Clark A; Dalby R; Dolovich M; Fleming J; Gehr P; Gonda I; O'Callaghan C; Taylor G; Newman S
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S39-57. PubMed ID: 21133799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles.
    Oberdorster G
    Inhal Toxicol; 1996; 8 Suppl():73-89. PubMed ID: 11542496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary drug delivery: medicines for inhalation.
    Henning A; Hein S; Schneider M; Bur M; Lehr CM
    Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
    Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic-pharmacodynamic relationship.
    Baggot JD
    Ann Rech Vet; 1990; 21 Suppl 1():29S-40S. PubMed ID: 2080844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids.
    Padden J; Skoner D; Hochhaus G
    J Asthma; 2008; 45 Suppl 1():13-24. PubMed ID: 19093281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhalation aspects of therapeutic aerosols.
    Leach CL
    Toxicol Pathol; 2007 Jan; 35(1):23-6. PubMed ID: 17325969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic optimisation of asthma treatment.
    Taburet AM; Schmit B
    Clin Pharmacokinet; 1994 May; 26(5):396-418. PubMed ID: 7914480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Pharmacokinetics of Inhaled Drugs.
    Taylor G
    J Aerosol Med Pulm Drug Deliv; 2023 Oct; 36(5):281-288. PubMed ID: 37851977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.
    Chen ML
    Clin Pharmacokinet; 2006; 45(10):957-64. PubMed ID: 16984210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
    Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
    J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model.
    Daley-Yates PT; Richards DH
    Clin Ther; 2004 Nov; 26(11):1905-19. PubMed ID: 15639702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs.
    Barros AS; Costa A; Sarmento B
    Adv Drug Deliv Rev; 2021 Mar; 170():386-395. PubMed ID: 32971227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
    Jones RM; Harrison A
    Xenobiotica; 2012 Jan; 42(1):75-85. PubMed ID: 22077102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.